Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Mark A. Dawson"'
Autor:
Mark A. Dawson
Publikováno v:
Nature Cancer.
Autor:
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Autor:
Mark A. Dawson
Publikováno v:
Cancer Research. 81:PL01-04
All cancers emerge following a period of clonal selection and subsequent clonal expansion. Whilst the evolutionary trajectories and clonal fitness imparted by genetic intra-tumour heterogeneity (ITH) are becoming increasingly clear, little is known a
Publikováno v:
Experimental Hematology. 90:1-11
Whilst DNA cytosine methylation is the oldest and most well-studied epigenetic modification, basking in its glory days, it may be soon overshadowed by the new kid on the block: RNA adenosine methylation. This juxtaposition is indeed superficial, and
Publikováno v:
Nature Reviews Drug Discovery. 19:776-800
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote cancer onset and progression. Although defective gene regulation often affects oncogenic and tumour-suppressor networks, tumour immunogenicity and immune cells inv
Autor:
Ken Doig, Andrew J. Colebatch, Devbarna Sinha, Christopher P. Mintoff, Grant A. McArthur, Paul Yeh, Carleen Cullinane, Maria Joao Silva, Shahneen Sandhu, David E. Gyorki, Mark Shackleton, Kathryn Alsop, Gisela Mir Arnau, Anthony T. Papenfuss, Sarah Ftouni, David D.L. Bowtell, Jason Li, Sarah-Jane Dawson, Jeanette Raleigh, Fergal C. Kelleher, Athena Hatzimihalis, Benjamin Brady, Mark A. Dawson, Stephen Q. Wong, Rodney J. Hicks, Heather Thorne, Jason Callahan, Damien Kee, Ismael A. Vergara, Timothy Semple
Publikováno v:
JCO precision oncology. 1
Purpose Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by 18F-labeled fluorodeoxyglucose posi
Autor:
Kah Lok Chan, Juliana Gomez, Chelisa Cardinez, Nishi Kumari, Christina E. Sparbier, Enid Y.N. Lam, Miriam M. Yeung, Sylvain Garciaz, James A. Kuzich, Doen Ming Ong, Fiona C. Brown, Yih-Chih Chan, Dane Vassiliadis, Elanor N. Wainwright, Ali Motazedian, Andrea Gillespie, Katie A. Fennell, Junyun Lai, Imran G. House, Laura Macpherson, Ching-Seng Ang, Sarah-Jane Dawson, Paul A. Beavis, Andrew H. Wei, Marian L. Burr, Mark A. Dawson
Publikováno v:
Cancer cell. 40(10)
There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expression in anti-cancer immunity. Relapse of acute myeloid leukemia (AML) following allogeneic stem cell transplantation (a
Autor:
Marc G. Achen, Niko Thio, Omer Gilan, Michael Y. He, Leigh Coultas, Michael M. Halford, Zoe L. Grant, Steven A. Stacker, Yih-Chih Chan, Ruofei Liu, James P. Roy, Mark A. Dawson
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Communications Biology
Communications Biology
Angiogenesis underlies development, physiology and pathogenesis of cancer, eye and cardiovascular diseases. Inhibiting aberrant angiogenesis using anti-angiogenic therapy (AAT) has been successful in the clinical treatment of cancer and eye diseases.
Autor:
Kathleen C. Rayeroux, Jason Li, Omer Gilan, Sarah Ftouni, Daniel H.D. Gray, Kathy Knezevic, Constantine S. Tam, Sarah-Jane Dawson, Meaghan Wall, Adrian Zordan, Mark A. Dawson, Charis E Teh, Rachel Thijssen, Tane Hunter, Stephen Q. Wong, Yih-Chih Chan, Mary Ann Anderson, David C.S. Huang, Christiane Pott, Charles C. Bell, Dane Vassiliadis, Piers Blombery, Enid Y.N. Lam, John F. Seymour, Rishu Agarwal, Andrew W. Roberts, Paul Yeh
Publikováno v:
Nature Medicine. 25:119-129
Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma. However, strategies to enable the evaluation of therapeutic response are required. Our prospective analyses of patients within the AIM study revealed genomic profile
Autor:
Veerle W. Daniels, Enid Y.N. Lam, Paloma Cejas, Clifford A. Meyer, Omer Gilan, Mark A. Dawson, Raga Vadhi, Ian E. Krop, Xintao Qiu, Bogdan Pasaniuc, Cynthia X. Ma, Len Taing, Klothilda Lim, Henry W. Long, Nikolas Kesten, Matthew J. Ellis, April C. Watt, Claudia Giambartolomei, Charles C. Bell, Rhiannon Coulson, Shom Goel, Eric P. Winer, Keegan Korthauer, Otto Metzger-Filho, Molly J. DeCristo, Jean J. Zhao, Alba Font-Tello, Haley BrinJones, Anthony Letai, Matthew L. Freedman, Ji-Heui Seo, Myles Brown, Joan Montero
Publikováno v:
Nature cancer, vol 2, iss 1
Nat Cancer
Nat Cancer
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent studies have suggested that these agents also exert other effects, influencing cancer cell immunogenicity, apoptotic respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07391ad275d64c17c054e5bd0859ea39
https://escholarship.org/uc/item/0b43x9f8
https://escholarship.org/uc/item/0b43x9f8